Choriocarcinoma is a biological curiosity. It is a fetal tumour which, arising from the trophoblast, invades the maternal host. This naturally occurring malignant allograft appears, with the exception of one rhesus monkey (Lindsey et al. 1969 ) and a thalidomide-treated, nine-banded armadillo (Marin-Padilla & Benirshke 1963) , to be unique to the human. Despite the dangers of extrapolating from the exception to the general it is clear that a study of the special features of rare tumours can throw light on the management of the more common forms of neoplasm.
The introduction of chemotherapy for trophoblastic tumours (Li et al. 1956 ) can be seen twenty years later to have been a turning-point in cancer therapy. Up to that time cytotoxic agents had scarcely gained respectability and the pattern of surgical and radiotherapeutic management changed but slowly. The responses of some choriocarcinomas to methotrexate revealed for the first time the potential of drugs to eradicate multiplesite metastatic disease. Unfortunately, only about 25 % of patients with choriocarcinoma achieved sustained remissions with methotrexate alone and the problem of drug resistance has been the subject of much of the subsequent research on this tumour.
Prognostic Factors
By collecting a substantial body of data it has been possible to analyse a wide range of factors which have influenced the prognosis of patients treated by chemotherapy for trophoblastic tumours (Bagshawe 1976a) . These include the patients' age and parity, type of pregnancy preceding the tumour, the estimated age of the tumour as indicated by the interval between the end of the last known pregnancy and the start of chemotherapy, the bulk of disease as indicated by the value for human chorionic gonadotrophin (HCG) in plasma or urine, the ABO group of the patient and her husband, the number of metastases, the sites of metastases, the size of metastases, the extent of lymphocyte infiltration in the tumour, the patient's immune status, and whether she had previously received chemotherapy. Undoubtedly, other factors also influence prognosis, and notably the important morphological distinction between choriocarcinoma and invasive mole. Yet the pursuit of a histological diagnosis does not justify hysterectomy when the diagnosis and prognosis can be determined by other means and the lesion eradicated without loss of fertility. The ability to detect and diagnose cancer biochemically and to do so at a subclinical stage has long been possible for trophoblastic tumours and it is one that is gradually extending to other tumours. New problems arise when treatment proceeds without histological confirmation and as biochemical diagnosis extends so these problems can be expected to become increasingly frequent.
After defining these prognostic factors it became appropriate to consider their relative weights. For instance, the patient's age has a weak influence on prognosis, but the 'age' of the tumour, that is the interval between antecedent pregnancy and the start of chemotherapy, was a powerful factor (Bagshawe 1976a) . On this basis relative weights were applied, using a simple scoring system -0, 10, 20, 40, -the highest score being applied to the most adverse factors. The scores for the different factors were added together to give a total score.
The series was then analysed for the effect of total score on prognosis and it showed that those with low scores had virtually a 100% survival record and those with the highest scores a 100% fatality rate, with a fair correlation between survival rate and score for intermediate values. The analysis also revealed that the improvements in our chemotherapeutic methods between 1957 and 1973 had been confined to patients in the middle-risk group and that no progress, as far as long-survival was concerned, had been made in the highest risk group. However, defining prognosis at the outset of treatment has made it possible to re-plan treatment for the highest score patients and since 1973 a few sustained remissions in this group can be recorded. No less important is the ability to define patients whose disease will predictably respond to less intensive treatment and achieve remission without incurring alopecia or other serious toxicity (Bagshawe 1976b ).
Long-term Effects of Cytotoxic Agents
One concern which arises from the growing use of cytotoxic agents and the long-term survival of patients so treated is the possible consequence of second cancers and of genetic effects on children born subsequently. This is particularly relevant in the young woman affected by choriocarcinoma. In over 400 successfully treated patients we have so far only one instance of a second tumour. This was an early cervical carcinoma-in-situ in a patient treated for choriocarcinoma six years earlier. A detailed analysis of 36 of more than 100 children born to these patients after chemotherapy found no effect which could be attributed to chemotherapy (Walden & Bagshawe 1976) . In a study in the USA similar data have been obtained (Van Thiel et al. 1970) . The data are not adequate, however, to exclude some increase in congenital defects and it must be accepted that in matters of such potential importance a critical outlook must be sustained and the unnecessary use of potential mutagens avoided in patients of reproductive age, especially for conditions such as benign hydatidiform mole. In any event, it is possible that the seemingly low incidence of second tumours and of genetic effects is related to the specific drugs used and to the intermittent pulse type of therapy used to treat choriocarcinoma since the late 1950s.
Tumour Monitoring
Some of the lessons which choriocarcinoma teaches us can be illustrated in relation to its tumour marker. This tumour was of course the first for which adequate marker measurements could be made and I have already referred to the strong prognostic indication from HCG concentration in body fluids at the start of treatment.
The superiority of a tumour secretion product compared with physical diagnostic methods for monitoring disease is illustrated by the fact that in none of the 500 treated cases have HCG measurements failed to correlate with other evidence. In the clinically disease-free state persisting HCG production has, sooner or later, been followed by clinical or radiological evidence of disease and, if not eradicated, by death. Similarly, persisting undetectability of HCG has invariably been accompanied by freedom from clinical recurrence. This is not to say that the minimum viable mass of tumour can be detected. Indeed the smallest amount of tumour we can detect is of the order of 104-105 cells. The limitations of tumour markers have to be understood if the results obtained with them are not to be wasted or misinterpreted.
Frequently, persisting HCG activity is detected after radiological regression. Occasionally we see the converse and some large radiological opacities may take a year or more to resolve after discontinuing therapy and after HCG values have become normal.
The promptness with which resistance can be detected is important since repeated exposure to ineffective drug regimen needs to be avoided. This is at its most impressive where the disease is subclinical and HCG measurements allow us to detect subclinical cancer, find its resistance and sensitivity and destroy it with drugs. It may be a long time before this can be done for many other tumours but it is the ultimate challenge for oncology.
The prompt recognition of drug resistance brings into focus the question whether drugs should be used sequentially or concurrently. There is unlikely to be a universal answer and that for particular tumours is likely to change. But what does not change is the objective of selective discrimination and the fact that one has only a limited number of 'shots' at the target. With about 7-18 days for a complete treatment-response cycle each ineffective regimen allows the tumour to gain ground and seems to promote resistance. The carefully planned regimen employing both sequential and multi-drug principles may have a place where advanced disease must first be made to regress at all costs and also where the likelihood of drug resistance is known, from prognostic factors, to be high.
On the other hand it can be argued that not all effective drugs should be used in one regimen, since this compromises their dosage and if a resistant clone emerges there is no fall-back therapy. Choriocarcinoma's behaviour indicates some validity in this argument, and the situation sometimes occurs where a vast burden of tumour is reduced to what is probably a few thousand cells but no means are left to eradicate that small number. The ability to monitor the course of this disease by bioassay in the 1950s established that the regimen of low daily dose of antimetabolites was far less effective in reducing tumour bulk than intermittent therapy and more likely to induce drug resistance. Unfortunately the evidence is largely anecdotal and an attempt to confirm it now would raise ethical problems. The timing of in-termittent therapy can be critical. If the interval between successive courses, that is the rest phase, exceeds the time required for haemopoietic recovery, then regrowth of tumour in the rest phase can exceed the cyto-reduction achieved during the treatment phase. This may not matter in tumours where the therapeutic objective is temporary control, but if the objective is cure, as it is in choriocarcinoma, then a progressive step-wise cyto-reduction is necessary and widely spaced treatments are unlikely to succeed.
Central Nervous System Localization The measurement of arteriovenous gradients for tumour markers can be used to localize occult disease. In practice the opportunities to do so are rare and the physical techniques of localization have improved so much in recent years that in most locations they are superior. One situation where markers can be more sensitive than computerized axial tomography is the brain, and disturbance in the plasma/CSF ratio for HCG allows the detection of brain metastases from choriocarcinoma at a very early stage (Bagshawe & Harland 1976 ). If brain metastases are detected before systemic chemotherapy is started, eradication of the brain lesion has been possible in many cases with chemotherapy which includes high-dose systemic methotrexate and intrathecal methotrexate. However, if the lesion has developed some time after systemic chemotherapy has started, even this very early detection system has not proved adequate, and therapy has almost invariably failed to achieve sustained remission. In patients judged to be at high risk of developing brain metastases, prophylactic therapy with each course of therapy has therefore been introduced; although it is too early to analyse the results they appear to be very encouraging. The blood/brain barrier provides a sinister sanctuary for malignant cells but its properties are open to exploitation.
Screeningfor Choriocarcinoma
The national scheme for following all UK patients by HCG radioimmunoassay for two years after hydatidiform mole was probably the first biochemical screening service to be set up for any form of cancer. The situation is ideal since these are young patients at high risk, for a limited period of time, of a curable tumour. It is difficult to cost such a scheme rigorously but it appears to work out at about £1000 per patient requiring treatment. This figure may seem high, yet it has to be offset not only against the lives it undoubtedly saves but against the cost of the alternatives. If patients developing choriocarcinoma are not admitted until they develop symptoms their treatment takes on average about three months longer than those selected by the screening programme and treat-ment costs some £4000£5000 more. It would be wrong to extrapolate these considerations to other screening situations, but in estimating costs both sides of the equation have to be calculated. The benefits of a tumour marker as precise as HCG are such that I have long felt that if there were such markers available for other tumours, we could, even without additional drugs, improve therapeutic schedules.
Set against this, however, was our experience with the malignant teratomas, where we had for many cases the same marker. The poor survival figure for patients with non-gestational choriocarcinomas was often attributed to their isogeneic nature in contrast to the allogeneic gestational tumour. This argument was discounted by the fact that some primary ovarian teratomas with trophoblastic elements responded well with sustained remissions. Yet for years the results with the testicular choriocarcinoma could be summarized as good initial responses but failure to achieve sustained remissions. Then with more effective drug combinations some successes began to be achieved. Later came the recognition of alphafetoprotein (AFP) as a second important marker for nontrophoblastic components in these tumours, and since, the rate of progress has accelerated. The tumour markers here provide prognostic information additional to that from the histopathological examination. We have therefore moved from the situation of having a marker but no effective therapy to that of having multiple markers and progressively improving therapy. Yet with advanced disease it remains difficult to achieve sustained remission and greater efforts are needed to ensure the effective application of tumour markers to detect early disease. It is most important that, when the otherwise asymptomatic young male presents with a seemingly trivial testicular complaint, the serum should be tested for HCG and AFP.
Immunotherapy
By 1968 we had treated quite vigorously some 30 women with minimal residual disease, using a variety of active specific and nonspecific immunization procedures (Bagshawe & Golding 1970 ). The problems of combining effective chemotherapy and immunotherapy became apparent. Of the 30 patients there was one in whom it seemed likely that immunization had been instrumental in achieving remission; she relapsed after seven years. The only other relapses in the series so far have been within two years of completing therapy.
The only real lesson to be drawn from our experience with attempted immunotherapy is that our knowledge is still too fragmentary to allow us to manipulate immune processes with the desired effect, but this does not mean that the immune response to the tumour, as it occurs naturally, plays no part in the tumour's natural history or response to chemotherapy. The idea that the immune response can eliminate the small tumour cell mass remaining after surgery, radiotherapy and chemotherapy is still unproven, although it may sometimes do so.
The fact that we still cannot adequately account for the non-rejection of the normal fetus and normal trophoblast in outbred mammalian pregnancy should encourage us to continue the search for the mechanisms involved. It may have implications for more than just choriocarcinoma. The suspicion that the placental secretory products, HCG, human placental lactogen, and pregnancyspecific /l3-glycoprotein, play a role in immunological escape has existed for some years although the evidence remains conflicting. Recent evidence (Naughton et al. 1975 , Horne et al. 1976 ) that these substances may be demonstrated in the periphery of many of the nontrophoblastic tumours of man, by histochemical techniques, is therefore interesting if not yet proven beyond doubt. There is even some evidence of HCG reactive material in experimental tumours (Acevedo et al. 1976 ). In our laboratory Wass and Rawlins have obtained evidence that there are both cellular (Wass et al. 1977) and humoral responses to HCG. It remains to be seen whether such responses are major actors or just extras in this elaborate play.
The fact is that we do not yet know why choriocarcinoma escapes immune rejection. Nor do we know why chemotherapy is effective against the majority of these tumours. Indeed, we do not yet know why cytotoxic agents achieve selective action against any human tumour, and I suggest that this remains one of our most interesting problems. For if it could be solved surely the road would be opened to a more rational approach to the design of new agents.
Implications of Cancer Chemotherapy
Despite limitations however, it is clear that cancer chemotherapy has itself become a proliferative process. With one or two new agents added each year it is now the biggest growth area in pharmacology. With each drug added the possible combinations and sequences increase in geometric series, a problem not encountered to this extent in other branches of therapeutics. This provides complexity enough, but the picture is given yet another dimension by the fact that each type of cancer responds to cytotoxic agents in a more or less individualistic fashion, and even within the same histological class of disease subtypes are observed. So we now see that chemotherapy has added, not just another modality of treatment to the earlier modalities of surgery and radiotherapy, but a totally new dimension. With the present agents the trend is for each type of cancer to require specifically tailored therapy to obtain the best possible results.
What I have described for choriocarcinoma is becoming true for many other tumours. The longterm implications of this for medicine in general are profound. We are only at the beginning of the era of treating cancer with drugs and of detecting cancer by chemical tests. But major organizational errors at this time could have repercussions on the way we handle these problems for many decades to come. To contend with the problems now emerging in cancer medicine, specialized experience and knowledge will become ever more necessary. Cancer medicine is not a career for those who prefer the soft option and the quick road to consultant status. The oncological connexion with internal medicine can be used to bring additional experience from experimental medicine, pharmacology, biochemistry and biophysics into clinical cancer practice. It is difficult to see how its practitioners can be effective radiotherapists or surgeons as well. It is a problem which the Collegiate structure of the profession in the UK could easily aggravate, but which it could also help remedy. It is to be hoped that the future of oncology at the professional level will lie, not, as a recent Lancet annotation (1976) implied, in demarcation disputes but in the coordination and integration of different disciplines.
